country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-180211

Copy Link Print Information

cGAS-IN-8

cGAS-IN-8 is an indazole cyclic GMP-AMP synthase (cGAS) inhibitor with an IC₅₀ of 6 nM for human cGAS. cGAS-IN-8 inhibits cGAMP production in THP-1 cells with an IC₅₀ of 0.12 µM. cGAS-IN-8 does not inhibits hERG activity. cGAS-IN-8 can be used for the research of autoimmune diseases.

For research use only. We do not sell to patients.

Formula: C₁₈H₁₈ClF₄N₅O₄
Molecular Weight:479.81

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (270 KB)

cGAS-IN-8 Chemical Structure

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

In Vitro

cGAS-IN-8 (compound 26) exhibits favorable hERG, no CYP3A4 inhibition and no GSH adducts are observed in human hepatocytes^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Parmacokinetics

Species	Dose	Route	CL	V_ss	T_1/2	F
Mice	0.5 mg/kg	i.v.	10.4 mL/min/kg	1.3 L/kg	2.1 h	111 %
Mice	5 mg/kg	p.o.	10.4 mL/min/kg	1.3 L/kg	2.1 h	111 %

In Vivo

cGAS-IN-8 (compound 26) (0.5 mg/kg, 5 mg/kg, i.v. and p.o.) demonstrated favorable pharmacokinetic and safety profiles in mice, with high oral bioavailability and no significant toxicity in C57Bl/6 female mice with pharmacokinetic and safety profiling^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

Molecular Weight 479.81
Formula C₁₈H₁₈ClF₄N₅O₄
SMILES

N#CCNCC(N1[C@@H](C)C2=C3C=C(OC)C(Cl)=C(F)C3=NN2CC1)=O.O=C(O)C(F)(F)F
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (270 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Patrick Cyr, et al. Reducing hERG Inhibition in the Design of Potent and Bioavailable Indazole cGAS Inhibitors. ACS Med. Chem. Lett. December 5, 2025.

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

100 mg

Get Quote In-stock